Abstract

To overcome the high relapse rate of multiple myeloma (MM), a drug delivery coating for functionalization of bone substitution materials (BSM) is reported based on adhesive, catechol-containing and stimuli-responsive polyelectrolyte complexes (PECs). This system is designed to deliver the MM drug bortezomib (BZM) directly to the anatomical site of action. To establish a gradual BZM release, the naturally occurring caffeic acid (CA) is coupled oxidatively to form poly(caffeic acid) (PCA), which is used as a polyanion for complexation. The catechol functionalities within the PCA are particularly suitable to form esters with the boronic acid group of the BZM, which are then cleaved in the body fluid to administer the drug. To achieve a more thorough control of the release, the thermoresponsive poly(N-isoproplyacrylamide-co-dimethylaminoethylmethacrylate) (P(NIPAM-co-DMAEMA)) was used as a polycation. Using turbidity measurements, it was proven that the lower critical solution temperature (LCST) character of this polymer was transferred to the PECs. Further special temperature dependent attenuated total reflection infrared spectroscopy (ATR-FTIR) showed that coatings formed by PEC immobilization exhibit a similar thermoresponsive performance. By loading the coatings with BZM and studying the release in a model system, via UV/Vis it was observed, that both aims, the retardation and the stimuli control of the release, were achieved.

Highlights

  • Multiple myeloma (MM) is still one of the most deadly malign bone diseases, esteemed to cause the death of approximately 13,000 people in the USA in 2019 [1]

  • Further special temperature dependent attenuated total reflection infrared spectroscopy (ATR-FTIR) showed that coatings formed by polyelectrolyte complexes (PECs) immobilization exhibit a similar thermoresponsive performance

  • The structure of the yielded product was analyzed by various methods including dynamic light scattering (DLS), infrared spectroscopy (FTIR), electrospray ionization mass spectroscopy (ESI-MS), nuclear magnetic resonance (NMR) and colloid titration (PCD), aiming at determination of the molecular weight and closer insights into the coupling mechanism

Read more

Summary

Introduction

Multiple myeloma (MM) is still one of the most deadly malign bone diseases, esteemed to cause the death of approximately 13,000 people in the USA in 2019 [1]. The relatively low five-year survival rate of 52.2% is due to the high relapse probability caused by the survival of the cancer cells in nearly impenetrable microlesions in the bone substance [1,2,3]. The high doses cause severe side effects, often weakening the patients gravely and thereby aiding the susceptibility towards relapses [3,4]. Due to these disadvantages and the persistently high death rate with the patients, MM is still considered to be an incurable disease [3,4]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call